Chiron Corp. reported robust third-quarter earnings, topping the Street's estimate by 14 cents per share, but also said it was dropping three late-stage programs, leaving some questioning the depth of its pipeline. (BioWorld Today)

Chiron Corp. reported robust third-quarter earnings, topping the Street's estimate by 14 cents per share, but also said it was dropping three late-stage programs, leaving some questioning the depth of its pipeline. (BioWorld Today)

When companies with three years of cash restructure to reduce spending - well, that might suggest they don't like the chances of the financing window opening anytime soon. (BioWorld Today)

When companies with three years of cash restructure to reduce spending - well, that might suggest they don't like the chances of the financing window opening anytime soon. (BioWorld Today)